DEFA14A: Glucotrack Urges Shareholder Vote on Equity Deal

Glucotrack, Inc. reminds shareholders to vote on an Equity Purchase Agreement with Sixth Borough Capital Fund at a Special Meeting on October 31, 2025.

Summary

• Glucotrack, Inc. is holding a Special Meeting of Shareholders on October 31, 2025, at 12 p.m. ET.
• Shareholders will vote on an Equity Purchase Agreement with Sixth Borough Capital Fund.
• The Board of Directors unanimously recommends that shareholders vote FOR all proposals.
• Shareholders of record as of September 23, 2025, are entitled to vote.
• The company encourages all eligible shareholders to vote as soon as possible via telephone, online, or proxy card.

Sentiment

Score: 6

Explanation: The filing indicates proactive corporate governance and a clear path for a potential capital raise to fund ongoing development of a promising medical device. However, it also highlights significant risks associated with capital, regulatory approvals, and clinical trials, which are inherent to the medical technology sector at this stage.

Positives

• The company is actively engaging shareholders for a significant corporate action, the Equity Purchase Agreement, which is crucial for its financial strategy.
• The Board of Directors unanimously supports the proposals, indicating strong internal alignment and confidence in the proposed agreement.
• Glucotrack is developing a novel, long-term implantable continuous blood glucose monitoring (CBGM) system with a 3-year sensor longevity and no on-body wearable component, addressing a key market need for people with diabetes.

Negatives

• The necessity of an Equity Purchase Agreement suggests a requirement for additional capital, which could lead to dilution for existing shareholders.
• The CBGM system is currently an Investigational Device, indicating it is not yet approved for commercial use and faces significant regulatory hurdles and development timelines.

Risks

• Ability to raise additional capital to finance operations, whether through public or private equity offerings, debt financings, strategic collaborations, or otherwise.
• Risks relating to the receipt and timing of regulatory approvals, including U.S. Food and Drug Administration (FDA) approval.
• Risks relating to enrollment of patients in, and the conduct of, clinical trials.
• Risks relating to future distribution agreements.
• Risks relating to the ability to hire and retain qualified personnel, including sales and distribution personnel.
• Additional risk factors described in Glucotrack's filings with the SEC, including its Annual Report on Form 10-K for the year ended December 31, 2024.

Future Outlook

Glucotrack is currently developing a long-term implantable continuous blood glucose monitoring system for people living with diabetes, which is an Investigational Device. The company's future success is subject to its ability to raise additional capital, secure regulatory approvals, conduct clinical trials, establish distribution agreements, and retain qualified personnel.

Management Comments

• "Glucotrack strongly encourages all shareholders to vote their shares as soon as possible."
• "The Board of Directors unanimously recommends that shareholders vote FOR all proposals."
• "Every vote is important, and the Company encourages ALL shareholders to participate to ensure their shares are represented by voting as soon as possible so their votes are tabulated before the meeting date."

Industry Context

Glucotrack operates in the competitive and rapidly evolving medical technology sector, specifically targeting the diabetes management market. The development of a long-term implantable continuous blood glucose monitoring system positions the company within the innovative segment of this industry, aiming to provide a less intrusive and more convenient solution compared to existing wearable or short-term implantable devices. The need for an Equity Purchase Agreement highlights the significant capital requirements typical for medical device companies in the development and regulatory approval phases.

Stakeholder Impact

• Shareholders are directly impacted by the vote on the Equity Purchase Agreement, which could lead to dilution but also provide necessary capital for company operations and development. They are encouraged to participate in the voting process.
• Employees may benefit from continued development of the CBGM system and securing capital, which could ensure job stability and future growth opportunities.
• Future customers could benefit from the successful development and commercialization of the CBGM system, offering a novel and improved solution for diabetes management.
• Sixth Borough Capital Fund will become a significant equity holder if the agreement is approved.

Next Steps

• Shareholders to vote on the Equity Purchase Agreement by October 31, 2025.
• Glucotrack to continue development and commercialization of its long-term implantable continuous blood glucose monitoring system.
• Pursue regulatory approvals (e.g., FDA) for its Investigational Device.
• Enroll patients in and conduct clinical trials.
• Establish future distribution agreements.

Key Dates

Recommendation

The filing outlines a critical shareholder vote on an Equity Purchase Agreement, which is essential for Glucotrack to secure funding for its promising, yet early-stage, implantable continuous blood glucose monitoring system. While the technology has potential, the company faces significant risks related to capital raising, regulatory approvals (FDA), and clinical trials. The unanimous board recommendation for the agreement is a positive signal, but the inherent uncertainties of a medical device in investigational use warrant a 'hold' position. Investors should monitor the outcome of the vote and subsequent progress in clinical development and regulatory pathways before making further investment decisions.

Keywords

Glucotrack, GCTK, Equity Purchase Agreement, Shareholder Meeting, Proxy Vote, Diabetes Technology, Continuous Glucose Monitoring, Medical Device, Sixth Borough Capital Fund, SEC Filing